$PRTK Paratek Pharmaceuticals started dosing the f
Post# of 36
Posted On: 11/09/2015 11:58:52 AM
$PRTK Paratek Pharmaceuticals started dosing the first patient in its Phase 3 clinical study of its lead drug candidate Omadacycline.
"This global Phase 3 study will assess the efficacy and safety of omadacycline compared with moxifloxacin in subjects with CABP."
Read More: http://investorshangout.com/post/view?id=3324...z3r0x0sKzX
"This global Phase 3 study will assess the efficacy and safety of omadacycline compared with moxifloxacin in subjects with CABP."
Read More: http://investorshangout.com/post/view?id=3324...z3r0x0sKzX
(0)
(0)Profile Technologies Inc. (PRTK) Stock Research Links
Scroll down for more posts ▼